BioPharmSignal logoBioPharmSignal

Biotech News

Acrivon Advances ACR-2316, a Potential First-in-Class WEE1/PKMYT1 Inhibitor, into Randomized Dose Expansion in its Ongoing Phase 1/2 Study

Acrivon Therapeutics (ACRV)Acrivon TherapeuticsClinical readout

Favorable, differentiated safety profile and durable single-agent clinical activity, including in heavily pretreated subjects with lung cancer remaining on treatment for over a year Oral weekly regimen (3 days on/4 days off) at 120 mg and 160 mg QD dose levels selected for randomized dose

Related news

IDYAIDEAYA Biosciences2026-07-27 10:00 EST

IDEAYA Biosciences Announces IDE892, a Potential Best-in-Class MTA-Cooperative PRMT5 Inhibitor, Initiates Part 2 Monotherapy Expansion in the Phase 1/2 Study in MTAP-Deleted Pancreatic and Lung Cancers

IDYAIDEAYA Biosciences2026-06-15 10:00 EST

IDEAYA Biosciences Announces IDE892, a Potential Best-in-Class MTA-Cooperative PRMT5 Inhibitor, Initiates a Phase 1/2 Clinical Combination Study in MTAP-Deleted Pancreatic and Lung Cancers

LEGNLegend Biotech Corporation2026-06-15 12:00 EST

Legend Biotech Establishes Clinical Proof-of-Concept for LB2501, a Potential First-in-Class In Vivo CD19/CD20 Dual-Targeting CAR-T, in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma

MGNXMacroGenics2026-07-23 20:01 EST

MacroGenics Provides Clinical Update on Ongoing Phase 1 Study for MGC026

KYMRKymera2026-06-12 11:00 EST

Kymera Therapeutics Presents Phase 1 Data in Healthy Japanese Adults for KT-621, a First-in-Class Oral STAT6 Degrader, at the Japanese Dermatological Association Annual Meeting

LYELLyell Immunopharma2026-06-08 10:00 EST

Lyell Immunopharma Provides Update on Safety Profile of LYL273 in Relapsed or Refractory Metastatic Colorectal Cancer and Amends Phase 1 Trial to Phase 1/2 Expansion

ERASErasca2026-07-13 20:01 EST

Erasca Announces Updated Preliminary Phase 1 Data and Registration-Enabling Plans for Potentially Best-in-Class Pan-RAS Molecular Glue ERAS-0015 in KRAS-Mutant Solid Tumors

RVMDRevolution Medicines2026-06-23 12:00 EST

Revolution Medicines Begins Treating Patients in RASolute 305, a Phase 3 Clinical Trial Evaluating Zoldonrasib in Combination with Chemotherapy as a First Line Treatment for Patients with RAS G12D Metastatic Pancreatic Cancer

NRIXNurix Therapeutics2026-08-04 11:00 EST

Nurix Announces $10 Million Milestone Payment Associated with Initiation of a Phase 1 Clinical Trial of a STAT6 Degrader

ACRVAcrivon Therapeutics2026-07-21 20:30 EST

Acrivon to Highlight the Power of its AP3 Platform for Streamlined, Pathway-Based Drug Discovery and Development with Oral and Poster Presentations at AACR D3 Conference

View all latest news

Acrivon Therapeutics

Generative Phosphoproteomics Platform Acrivon Therapeutics uses its AP3 platform to measure drug-regulated signaling inside intact cells and identify tumors most likely to respond to specific medicines. ACR-368 ACR-368 is a CHK1/2 inhibitor in a registrational-intent Phase 2b study, with increasing focus on serous endometrial cancer and...

Recent company news

ACRVAcrivon Therapeutics2026-08-05 12:30 EST

Acrivon Advances ACR-2316, a Potential First-in-Class WEE1/PKMYT1 Inhibitor, into Randomized Dose Expansion in its Ongoing Phase 1/2 Study

ACRVAcrivon Therapeutics2026-07-21 20:30 EST

Acrivon to Highlight the Power of its AP3 Platform for Streamlined, Pathway-Based Drug Discovery and Development with Oral and Poster Presentations at AACR D3 Conference

ACRVAcrivon Therapeutics2026-05-21 11:30 EST

Acrivon Therapeutics to Present at TD Cowen’s 7th Annual Oncology Innovation Summit

ACRVAcrivon Therapeutics2026-05-15 20:00 EST

Acrivon Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

ACRVAcrivon Therapeutics2026-05-13 20:10 EST

Acrivon Reports First Quarter 2026 Financial Results and Highlights Progress Towards Key 2026 Clinical Catalysts

Stock data

Close
1.69 USD
Market cap
67.2M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States